Jamun (Java Plum) for Blood Sugar

Jamun is the dark purple fruit of Syzygium cumini, an evergreen tree of the myrtle family that grows across the Indian subcontinent, Southeast Asia and East Africa. Research papers also use the tree's older name, Eugenia jambolana, and the common names jambolan, Java plum and black plum. The seeds, fruit, leaves and bark have all been used against diabetes, and when they were tested they did not give the same results.

State of the evidence: thin in people. The two randomized controlled trials with reported results tested a tea made from the leaves, and both found no effect on blood sugar. The seed is the part used in Indian household medicine and the part that lowered blood sugar in many animal studies, yet no randomized controlled trial of the seed with reported numbers is among the records reviewed for this page. A 2008 review of 125 years of research concluded that a state-of-the-art clinical study was still missing.

Table of Contents

  1. What the Plant Is and How It Has Been Used
  2. Why the Plant Part Matters
  3. Active Compounds and How They Act
  4. What Human Trials Found
  5. What Animal and Laboratory Studies Found
  6. Amounts Used in the Trials
  7. Safety Findings and Interactions
  8. Limits of the Evidence
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What the Plant Is and How It Has Been Used

A 2013 review describes Syzygium cumini as an evergreen tree distributed throughout the Indian subcontinent, Southeast Asia and East Africa. It is known as jamun in India and is grown mainly for its fruit and its timber (PMID 23460190). A 2022 review adds that the tree belongs to the Myrtaceae (myrtle) family, is cultivated mainly in Asian countries such as Pakistan, India, Sri Lanka and Bangladesh, and is also called black plum (PMID 36364010).

The tree has been published under several botanical names. A 2008 historical review lists Syzygium jambolanum and Eugenia jambolana as synonyms of Syzygium cumini (PMID 18380393). A paper on Eugenia jambolana and a paper on Syzygium cumini are therefore about the same tree. Other species that share the genus name Syzygium or Eugenia are different plants, and a result for one of them is not a result for jamun.

Traditional Use Against Diabetes

Different parts of the tree are used in different places:

A Long Research History

The 2008 historical review reports that the plant was studied extensively over 125 years and that approximately 100 case reports had been published before insulin was discovered. After the Second World War, research concentrated on animal studies. The review describes jamun as one of the medicinal plants most often recommended as an add-on (adjuvant) therapy in type 2 diabetes, and in the same abstract states that a state-of-the-art clinical study is still missing (PMID 18380393).

Back to Table of Contents

Why the Plant Part Matters

"Jamun" on a label can mean seed powder, fruit pulp, leaf or bark. The authors of a 2005 animal study wrote that the therapeutic potential of a plant is related to the geographic region where it was grown and to the part of the plant used (PMID 15588649). The records reviewed for this page bear that out: the results differ by plant part, and the part tested in randomized controlled trials (the leaf) is not the part that lowered blood sugar in animals (the seed).

Plant part Findings in people Findings in animals and the laboratory
Seed and seed kernel No randomized controlled trial with reported numbers among the records reviewed. About 100 case reports date from before the discovery of insulin. Lowered blood sugar in diabetic laboratory animals in several studies. In one study the effect shrank as the diabetes became more severe.
Fruit pulp and fruit residue No trial among the records reviewed. Null result: fruit-pulp extract for 41 days did not change blood sugar in diabetic rats. In a laboratory enzyme test, powdered fruit residue slowed two starch-digesting enzymes.
Leaf Null results: leaf tea had no effect in a randomized controlled trial in 30 healthy volunteers and none in a randomized controlled trial in 27 people with type 2 diabetes over 28 days. Null result: leaf extract for 2 weeks did not change blood sugar after meals in normal or diabetic rats. In a laboratory test on blood platelets, leaf extract prevented a rise in a marker of oxidative damage.
Stem bark No trial among the records reviewed. Named in a 2013 review as one of the parts reported for promising activity; the abstract gives no study details.

The 2013 review wrote that different parts of the plant, "especially fruits, seeds and stem bark", were reported for promising activity against diabetes (PMID 23642956). The leaf is not among the three parts that review singles out.

Back to Table of Contents

Active Compounds and How They Act

No single compound has been shown to be responsible for an effect of jamun on blood sugar. Two reviews by the same lead author, published in 2012 and 2013, both state that the active principles still need to be isolated and identified (PMID 23569906, PMID 23642956). What the reviews and laboratory analyses list is a set of candidates:

Three Proposed Actions, None Confirmed in People

Laboratory and animal studies point to three places where jamun preparations have been reported to act. The diagram shows each one with the kind of study it comes from.

Three places where jamun has been reported to act, each labelled with the kind of study behind it; none is confirmed in a human trial Where jamun has been reported to act, and the kind of study behind each report 1. In the gut Two starch-digesting enzymes (alpha-amylase and alpha-glucosidase) were slowed by powdered jambolan fruit residue. Slower starch digestion means sugar enters the blood more slowly. LABORATORY TEST → 2. In the pancreas Beta cells make insulin. In diabetic rats given seed kernel extract, the beta cells looked protected under the microscope, and markers of oxidative damage moved toward normal. DIABETIC RATS → 3. In liver and muscle Stored sugar (glycogen) in liver and muscle, and sugar-handling enzymes in the liver, were partly restored in diabetic mice given jamun. DIABETIC MICE Not confirmed in people. In the two randomized controlled trials with reported results, a tea made from jamun leaves did not change blood sugar.

In the gut. Alpha-amylase and alpha-glucosidase are the enzymes that break starch down into sugar. In a laboratory enzyme test, all four tropical fruit residue powders that were tested, jambolan among them, inhibited both enzymes (PMID 23014856). This was a test-tube measurement; nobody ate the powder.

In the pancreas. Beta cells are the cells of the pancreas that make insulin. In diabetic rats, tissue examined under the microscope showed a protective effect of seed kernel extract on the beta cells, alongside a fall in markers of oxidative stress (chemical damage caused by reactive forms of oxygen) (PMID 15369706).

In liver and muscle. Glycogen is the form in which liver and muscle store sugar. In diabetic mice, jamun partially restored the altered glycogen content of liver and skeletal muscle and the altered levels of several sugar-handling enzymes in the liver (PMID 11091000).

A fourth idea comes from the seed-ash study: its authors concluded that the minerals in the seed might play an important role in its effect, after rats given the ash showed normal blood sugar and better glucose tolerance (PMID 15235149). That, too, is a finding in rats.

Back to Table of Contents

What Human Trials Found

The human evidence among the records reviewed for this page consists of two randomized controlled trials of leaf tea, both with null results; one 2026 report comparing treated and untreated people, with no numbers in its abstract; and case reports from before the discovery of insulin. No record reports a randomized controlled trial of jamun seed powder, fruit or bark with glucose or hemoglobin A1C (HbA1c) figures. HbA1c is the blood test that reflects average blood sugar over roughly the previous three months.

Leaf Tea in Healthy Volunteers: No Effect

A randomized, parallel, placebo-controlled trial published in 2000 tested a tea prepared from jamun leaves in 30 young volunteers without diabetes. The volunteers underwent a glucose tolerance test, which tracks blood sugar after a measured amount of glucose. The tea showed no antihyperglycemic (blood-sugar-lowering) effect (PMID 10904184).

The authors wrote that these results "do not rule out hypoglycemic effects in patients with type 2 diabetes mellitus, but strongly suggest that, for a while, the jambolan can not be recommended as an antihyperglycemic treatment".

Leaf Tea in Type 2 Diabetes: No Effect

The same research group then tested the tea in people with type 2 diabetes. The trial, published in 2006, was randomized, double-blind and double-dummy: every participant received both a tea and tablets, so that neither participants nor researchers could tell who was getting which active treatment. There were three groups (PMID 16476114):

In total, 27 patients were allocated to the groups and followed for 28 days. Fasting blood glucose decreased significantly with glyburide. It did not change with jamun leaf tea, and it did not change with placebo. Because the drug group did show a fall, the trial was able to detect a drop in blood sugar where one existed.

Body mass index, creatinine (a kidney marker), four liver enzymes (gamma-glutamyl transferase, alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase), 24-hour urine glucose, 24-hour urine protein, triglycerides and total, low-density lipoprotein and high-density lipoprotein cholesterol did not vary significantly between the groups. The authors' conclusion: "Tea prepared from leaves of S. cumini has no hypoglycaemic effect."

A 2026 Report Comparing Treated and Untreated People

A paper published in 2026 describes people with diabetes separated into a group that received supplementation with Syzygium jambolanum (a synonym of Syzygium cumini) and a group that did not. The abstract reports that fasting blood glucose was significantly lower in the treated group than in the untreated group, and that HbA1c, liver enzymes, serum urea, uric acid, cholesterol and creatinine also showed "notable improvements" (PMID 41503906).

The abstract does not give the number of participants, the plant part, the amount, the length of treatment, or any glucose or HbA1c figure. It does not describe the study as randomized, blinded or placebo-controlled, and it does not state what other treatment either group was receiving. A comparison of treated and untreated people without those features cannot separate the effect of the supplement from differences between the two groups.

Seed and Fruit: Old Case Reports, No Modern Trial

The 2008 historical review counted approximately 100 case reports published before insulin was discovered (PMID 18380393). A case report describes what happened to individual patients, with no comparison group, so it cannot show whether the plant caused the change.

From the old literature and the later animal work, the reviewer concluded that a clinical study with a chance of success would need to use jamun seeds, seed kernels or fruit from India "in fairly high doses", and wrote that reductions in blood sugar of about 30% "seem reasonably to be expected". That 30% figure is the reviewer's expectation for a future trial. It is not a measured trial result, and no trial among the records reviewed for this page tested it.

What the Reviews Conclude

Review articles reach different conclusions about the human evidence:

Back to Table of Contents

What Animal and Laboratory Studies Found

Everything in this section was found in rats, in mice, or in laboratory tests on enzymes or blood cells. None of it was measured in people. In most of the animal studies, diabetes was produced with streptozotocin, a chemical that destroys the insulin-making cells of the pancreas. The 2008 historical review summed up the post-war animal work this way: "Not all, but many of them reported some success" (PMID 18380393).

Seed and Seed Kernel in Diabetic Rats and Mice

The effect shrank as diabetes became more severe (animal study). A 2000 study gave jamun preparations to animals with mild, moderate and severe chemically induced diabetes. In mild diabetes (plasma sugar above 180 mg/dl), the largest fall in glucose, 73.51%, was seen in animals receiving 200 mg per kilogram of body weight per day of freeze-dried (lyophilized) jamun powder, after 3 weeks of treatment. The abstract introduces the seed kernel as the part used in India but does not name the plant part behind the powder. The reduction was 55.62% in moderate diabetes (plasma sugar above 280 mg/dl) and 17.72% in severe diabetes (plasma sugar above 400 mg/dl) (PMID 11091000). The same study tested guduchi (Tinospora cordifolia), whose reduction in severe diabetes was 0%.

Antioxidant markers and beta cells (rat study). In rats with streptozotocin-induced diabetes, plasma glucose and markers of oxidative stress were raised and the antioxidant enzymes of the pancreas were altered. After treatment with an alcohol (ethanolic) extract of jamun seed kernel, or with the drug glibenclamide, these changes "reverted back to near normal level", and tissue examination showed a protective effect of the seed kernel on the beta cells of the pancreas (PMID 15369706). The abstract gives no glucose figures.

Seed ash (rat study). Researchers burned the seeds to ash, leaving only the minerals, and gave the ash to rats with streptozotocin-induced diabetes. The treated rats "exhibited normoglycemia", meaning normal blood sugar, and better glucose tolerance (PMID 15235149).

Seed extract given with a diabetes drug (rat study). Diabetic rats received a water extract of jamun seeds, the prescription drug sitagliptin, or both, for 28 days. The combination produced a significant reduction in blood glucose compared with the drug alone and with the extract alone, even though the extract lowered the amount of the drug in the blood (PMID 31453133). The drug-level finding is described under Safety Findings and Interactions.

Fruit Pulp in Diabetic Rats: No Effect

A Brazilian team tested fruit grown in Brazil, using the same preparation and methods that had been used in India. Rats with streptozotocin-induced diabetes (10 animals) received 50 mg per day of freeze-dried fruit-pulp extract by stomach tube for 41 days. Compared with untreated diabetic rats, the treated rats showed no observable difference in blood sugar, body weight, food or water intake, urine volume, urinary glucose, liver glycogen, or serum total cholesterol, high-density lipoprotein cholesterol or triglycerides (PMID 15588649).

The authors wrote that the lack of effect "may be attributable to the regional ecosystem where the fruit was collected and/or to the severity of the induced diabetes".

Leaf Extract in Rats and in a Platelet Test

No effect in rats. The group that ran the leaf-tea trials also gave increasing doses of a crude leaf extract to normal rats and to rats with streptozotocin-induced diabetes for 2 weeks, measuring blood sugar after feeding. The treatment produced no antihyperglycemic effect in either the normal rats or the diabetic rats (PMID 10904184).

Platelets in a laboratory dish. In a 2010 laboratory study, platelets (the blood cells involved in clotting) were taken from people with type 2 diabetes. The platelets showed higher activity of two enzymes, adenosine deaminase and 5'-nucleotidase, and higher levels of a marker of oxidative damage than platelets from the control group. Adding a water extract of jamun leaves to the samples, at 100 and 200 micrograms per millilitre, prevented these effects (PMID 21063110). The patients did not take the extract; it was added to their blood samples. The study did not measure blood sugar.

Fruit Residue in an Enzyme Test

A 2012 laboratory study analyzed powdered residues (seeds, peels and leftover pulp) from the processing of four tropical fruits, jambolan among them. All four powders inhibited alpha-amylase and alpha-glucosidase. The half-inhibition concentrations, the amount needed to cut enzyme activity by half, ranged from 3.40 to 49.5 mg of catechin equivalents per millilitre for alpha-amylase and from 1.15 to 2.37 mg of catechin equivalents per millilitre for alpha-glucosidase across the four fruits; the abstract does not give jambolan's own figures. Jambolan powder gave the highest reading of the four in one of the two antioxidant tests (PMID 23014856).

Back to Table of Contents

Amounts Used in the Trials

These are the amounts researchers gave. No amount of jamun has been shown in a randomized controlled trial to lower blood sugar in people, so none of the figures below is an established dose.

In People

In Animals and the Laboratory

An amount given per kilogram of a rat's or mouse's body weight does not convert directly into an amount for a person. Rodents handle plant compounds and drugs at different rates from people.

Back to Table of Contents

Safety Findings and Interactions

Safety data for jamun in people are sparse. The records reviewed for this page contain one 28-day trial with laboratory safety measures, one reviewer's expectation of side effects, and one drug-interaction study in rats.

Back to Table of Contents

Limits of the Evidence

Back to Table of Contents

Key Research Papers

  1. Teixeira CC, Fuchs FD, Weinert LS, Esteves J. The efficacy of folk medicines in the management of type 2 diabetes mellitus: results of a randomized controlled trial of Syzygium cumini (L.) Skeels. J Clin Pharm Ther. 2006;31(1):1-5. PubMed PMID: 16476114
  2. Teixeira CC, Rava CA, Mallman da Silva P, Melchior R, Argenta R, Anselmi F, et al. Absence of antihyperglycemic effect of jambolan in experimental and clinical models. J Ethnopharmacol. 2000;71(1-2):343-7. PubMed PMID: 10904184
  3. Roy A, Maiti DK, Banik BK. The Protective Effects of Syzygium Jambolanum Extracts on Diabetes. Curr Drug Discov Technol. 2026;:10.2174/0115701638414284251024094632. PubMed PMID: 41503906
  4. Helmstädter A. Syzygium cumini (L.) SKEELS (Myrtaceae) against diabetes--125 years of research. Pharmazie. 2008;63(2):91-101. PubMed PMID: 18380393
  5. Ayyanar M, Subash-Babu P, Ignacimuthu S. Syzygium cumini (L.) Skeels., a novel therapeutic agent for diabetes: folk medicinal and pharmacological evidences. Complement Ther Med. 2013;21(3):232-43. PubMed PMID: 23642956
  6. Rizvi MK, Rabail R, Munir S, Inam-Ur-Raheem M, Qayyum MMN, Kieliszek M, et al. Astounding Health Benefits of Jamun (Syzygium cumini) toward Metabolic Syndrome. Molecules. 2022;27(21):7184. PubMed PMID: 36364010
  7. Sagi S, Bojjala S, Muppuru Muni K, Arokia Vijaya Anand M. Advancing Diabetes Treatment Through NanoPhytotherapeutics: Uncovering the Therapeutic Promise of Syzygium Cumini, Pterocarpus Santalinus, and Momordica Cymbalaria. Curr Diabetes Rev. 2026;:10.2174/0115733998470934260630070603. PubMed PMID: 42483920
  8. Grover JK, Vats V, Rathi SS. Anti-hyperglycemic effect of Eugenia jambolana and Tinospora cordifolia in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. J Ethnopharmacol. 2000;73(3):461-70. PubMed PMID: 11091000
  9. Ravi K, Ramachandran B, Subramanian S. Effect of Eugenia Jambolana seed kernel on antioxidant defense system in streptozotocin-induced diabetes in rats. Life Sci. 2004;75(22):2717-31. PubMed PMID: 15369706
  10. Ravi K, Sekar DS, Subramanian S. Hypoglycemic activity of inorganic constituents in Eugenia jambolana seed on streptozotocin-induced diabetes in rats. Biol Trace Elem Res. 2004;99(1-3):145-55. PubMed PMID: 15235149
  11. Pepato MT, Mori DM, Baviera AM, Harami JB, Vendramini RC, Brunetti IL. Fruit of the jambolan tree (Eugenia jambolana Lam.) and experimental diabetes. J Ethnopharmacol. 2005;96(1-2):43-8. PubMed PMID: 15588649
  12. Vora A, Varghese A, Kachwala Y, Bhaskar M, Laddha A, Jamal A, et al. Eugenia jambolana extract reduces the systemic exposure of Sitagliptin and improves conditions associated with diabetes: A pharmacokinetic and a pharmacodynamic herb-drug interaction study. J Tradit Complement Med. 2019;9(4):364-371. PubMed PMID: 31453133
  13. Correia RT, Borges KC, Medeiros MF, Genovese MI. Bioactive compounds and phenolic-linked functionality of powdered tropical fruit residues. Food Sci Technol Int. 2012;18(6):539-47. PubMed PMID: 23014856
  14. De Bona KS, Bellé LP, Sari MH, Thomé G, Schetinger MR, Morsch VM, et al. Syzygium cumini extract decrease adenosine deaminase, 5'nucleotidase activities and oxidative damage in platelets of diabetic patients. Cell Physiol Biochem. 2010;26(4-5):729-38. PubMed PMID: 21063110
  15. Ayyanar M, Subash-Babu P. Syzygium cumini (L.) Skeels: a review of its phytochemical constituents and traditional uses. Asian Pac J Trop Biomed. 2012;2(3):240-6. PubMed PMID: 23569906
  16. Srivastava S, Chandra D. Pharmacological potentials of Syzygium cumini: a review. J Sci Food Agric. 2013;93(9):2084-93. PubMed PMID: 23460190

PubMed Topic Searches

  1. PubMed: Syzygium cumini and type 2 diabetes, clinical trials
  2. PubMed: Eugenia jambolana and diabetes
  3. PubMed: Syzygium cumini seed and blood glucose
  4. PubMed: Syzygium cumini antidiabetic reviews

Back to Table of Contents

Connections

Back to Table of Contents